Skip to search formSkip to main contentSkip to account menu

ANTI-INHIBITOR COAGULANT COMPLEX

Known as: coagulation factor IX, II, VII and X in combination, Factor VIII bypassing fraction, Factor VIII inhibitor bypassing activity 
A sterile, freeze dried fraction of human plasma containing factor VIII coagulant antigen and both the inactive and active forms of coagulation… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other… 
Review
2011
Review
2011
BackgroundResearch on health care utilization in low income countries suggests that patients frequently bypass PHC facilities in… 
Highly Cited
2007
Highly Cited
2007
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor… 
Highly Cited
2005
Highly Cited
2005
Summary.  In haemophilia patients with inhibitor, elective orthopaedic surgery is usually performed under recombinant activated… 
Review
2004
Review
2004
Summary.  Recombinant factor (rF)VIIa has been available to clinicians since 1996 and has an excellent safety record after almost… 
Highly Cited
2004
Highly Cited
2004
Summary.  Haemorrhagic manifestations in patients with acquired haemophilia can be fatal if not recognized and treated… 
Highly Cited
2004
Highly Cited
2004
  • L. Aledort
  • Journal of Thrombosis and Haemostasis
  • 2004
  • Corpus ID: 34862036
Summary.  Thrombosis is a rare but well‐recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA… 
Highly Cited
2003
Highly Cited
2003
Factor VIII (FVIII)-bypassing agents have complex modes of action but all control bleeding in inhibitor patients by triggering… 
Highly Cited
1997
Highly Cited
1997
Factor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the…